Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Memorial Sloan-Kettering’s Bach Balks At Drug Pricing

This article was originally published in The Pink Sheet Daily

Executive Summary

Peter Bach slammed the industry over high drug prices and practices such as rebating, which he said confound open debate about drug cost and benefit, during a panel discussion at the BIO CEO & Investor conference.

You may also be interested in...



Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment

Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.

Q3 Headwinds For Pharma Could Dampen A Continued Rally

COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.

Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma

Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel